Avadel Pharma (AVDL) Prices 11.63M ADS Offering at $10.75/ADS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall St on track for subdued September start as high yields, oil prices dent sentiment
- Oil up more than 2% as renewed US-Iran strikes stoke supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
- The Warsh pivot markets didn't expect
Avadel Pharma (AVDL) Announces Proposed $100M ADS Offering
April 28, 2020 5:49 AM EDTAvadel Pharmaceuticals plc (NASDAQ: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in patients with narcolepsy, announced today that it is commencing an underwritten public offering of $100 million in ordinary... More
Avadel Pharmaceuticals (AVDL) PT Raised to $17 at Stifel
April 27, 2020 4:29 PM EDTStifel analyst Paul Matteis raised the price target on Avadel Pharmaceuticals (NASDAQ: AVDL) to $17.00 (from $14.00) while maintaining a Buy rating.
... MoreAvadel Pharma (AVDL) Phase 3 REST-ON Trial of Once-Nightly FT218 for Treatment of Excessive Daytime Sleepiness and Cataplexy in Patients with Narcolepsy Met Endpoints
April 27, 2020 7:04 AM EDTAvadel Pharmaceuticals plc (Nasdaq: AVDL) announced today positive topline data from its pivotal Phase 3 REST-ON trial assessing the safety and efficacy of FT218, an investigational, once-nightly formulation of sodium oxybate for the treatment of excessive daytime sleepiness and cataplexy in patients with narcolepsy. The REST-ON trial, under a Special Protocol Assessment agreement with the FDA, met its three co-primary efficacy endpoints at all three doses (9 g, 7.5 g, and 6 g) demonstrating highly significant, clinically meaningful improvements on the Maintenance of Wakefulness Test (MWT), Clinical Global Impression-Improvement (CGI-I) and mean weekly cataplexy attacks.
... More
